AlphaCore Capital LLC Acquires 17,224 Shares of Abbott Laboratories $ABT

AlphaCore Capital LLC grew its holdings in shares of Abbott Laboratories (NYSE:ABT) by 157.8% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 28,137 shares of the healthcare product maker’s stock after buying an additional 17,224 shares during the period. AlphaCore Capital LLC’s holdings in Abbott Laboratories were worth $3,525,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Harbor Capital Advisors Inc. bought a new stake in shares of Abbott Laboratories during the 4th quarter valued at $27,000. Cloud Capital Management LLC bought a new stake in shares of Abbott Laboratories during the 3rd quarter valued at $29,000. Guerra Advisors Inc bought a new stake in shares of Abbott Laboratories during the 3rd quarter valued at $31,000. Bridge Generations Wealth Management LLC purchased a new position in shares of Abbott Laboratories in the 3rd quarter worth about $33,000. Finally, Copia Wealth Management purchased a new position in shares of Abbott Laboratories in the 3rd quarter worth about $38,000. Institutional investors own 75.18% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on ABT. Barclays lowered their price target on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a research report on Monday, April 20th. Daiwa Securities Group lowered Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price target for the company. in a research report on Wednesday, April 22nd. TD Cowen lowered their price target on Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, April 17th. UBS Group lowered their price target on Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating for the company in a research report on Monday, April 20th. Finally, Leerink Partners lowered their price target on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a research report on Tuesday, April 21st. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $119.43.

Insiders Place Their Bets

In other Abbott Laboratories news, SVP Eric Shroff sold 709 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the sale, the senior vice president directly owned 39,164 shares in the company, valued at $4,526,575.12. The trade was a 1.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Mary K. Moreland sold 613 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the sale, the executive vice president owned 104,291 shares of the company’s stock, valued at approximately $12,053,953.78. This represents a 0.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 3,055 shares of company stock worth $353,097 in the last quarter. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $84.49 on Friday. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $139.06. The business has a 50-day simple moving average of $99.02 and a two-hundred day simple moving average of $113.35. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The firm has a market cap of $147.16 billion, a price-to-earnings ratio of 23.67, a price-to-earnings-growth ratio of 1.41 and a beta of 0.65.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. During the same quarter in the previous year, the firm earned $1.09 EPS. Abbott Laboratories’s revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th were given a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 3.0%. Abbott Laboratories’s payout ratio is 70.59%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.